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Pulmonary Mucormycosis in a patient with
Acute Myeloid Leukemia
Jonathan Pan, MD, Margaret Kasner, MD, Sheel Patel, MD, Gretchen Diemer, MD

Introduction

Outcome and Follow up

Mucormycosis is a rare fungal infection that is common
amongst uncontrolled diabetics and immunocompromised patients. The most common clinical
presentation is rhino-orbital-cerebral infection, which
typically affects diabetics with ketoacidosis. 1 Less
commonly, pulmonary mucormycosis can occur in
patients with hematologic malignancy, solid organ
transplant and patients taking steroids or deferoxamine.1
The following report describes a 25-year-old male
with Acute Myeloid Leukemia (AML) who developed a
pulmonary mucormycosis infection. With a mortality
rate of about 87%, this case represents a favorable
outcome for a rare and often lethal diagnosis.

A CT-guided biopsy of the pulmonary consolidation
was performed. Pathology revealed granulomatous
inflammation with necrosis and silver stain showed
sparsely septate hyphae consistent with mucormycosis.
High-dose ambisome was initiated and the patient
began to demonstrate signs of clinical improvement.
He was discharged on a six-week course of intravenous
ambisome. Follow-up imaging showed improvement of
the consolidations and the patient was switched to oral
posaconazle for six additional weeks.

Case Description
A 25-year-old male with no past medical history presented
to the hospital after two weeks of fatigue, shortness of
breath and epistaxis. Lab work revealed leukocytosis
with 43% blasts, anemia and thrombocytopenia. A bone
marrow biopsy confirmed the diagnosis of AML. After
admission, the patient developed persistent fevers and
CT scan demonstrated ground-glass opacities in bilateral
lung fields. Blood and sputum cultures, respiratory
viral panel and acid fast studies were negative and the
patient was started on antifungals and broad spectrum
antibiotics. Bronchoscopy with bronchoalveolar
lavage did not reveal an infectious source. The patient
underwent induction chemotherapy with idarubicin and
cytarabine, which was initially well tolerated. However,
he soon developed neutropenic fever, hypoxia, and a
non-productive cough. The treatment was broadened
from vancomycin, zosyn and micafungin to meropenem
and ambisome. Cultures remained negative during this
time and subsequent imaging revealed right-middle and
left-upper lobe consolidations with a central lucency.
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Discussion
Mucormycosis is a rare opportunistic fungal infection
caused by fungi in the mucorales order, including
mucor, rhizopus and absidia.3 These fungi are ubiquitous
in nature, commonly found in soil and decaying matter
and released via airborne spores. Histologically, hyphae
are seen in broad, irregular branches with few septations,
as opposed to aspergilli, which have acute branching
angles and many septations. Comprising a unique
category of angioinvasive molds, tissue infarction is a
hallmark of the disease process.4 Risk factors include
diabetes, hematologic malignancy, solid organ or stem
cell transplant, immunocompromised state, iron overload
and treatment with deferoxamine.5 While incidence is
difficult to estimate due to mucormycosis not being a
reportable disease, it is estimated that approximately 500
cases occur in the US each year.6 As rhino-orbital-cerebral
infection is the most common clinical manifestation in
diabetics, pulmonary mucormycosis is more commonly
seen with hematologic malignancy, transplant patients
and steroid or deferoxamine use. It is caused by direct
inhalation of spores into bronchioles and alveoli, which
presents as a rapidly progressing pneumonia with or
without hemoptysis.7 Clinical presentation is similar to
that of other angioinvasive molds such as aspergillus or
fusarium, and diagnosis is therefore obtained by culture
and pathology. Imaging can show non-specific findings
such as focal consolidation, nodules, masses, or pleural
effusions. A halo sign on CT scan, which shows ground
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glass attenuation surrounding a nodule, is characteristic
of pulmonary aspergillus. A reverse halo-sign, on the
other hand, shows focal ground glass attenuation within
a ring of consolidation and is more commonly seen with
mucormycosis. As cultures are typically negative, tissue
diagnosis is often pursued. A biopsy with silver stain will
typically reveal broad, irregular, branching hyphae.
In cases where pulmonary mucormycosis is localized to a
single lobe, surgical excision can be performed. However,
first line treatment for pulmonary mucormycosis remains
high-dose, intravenous amphotericin B. Liposomal
amphotericin is preferred due to improved efficacy and
safety, although renal function and electrolytes must
nonetheless be carefully monitored. Treatment should
be initiated for several weeks until the patient clinically
improves. At this time, amphotericin may be switched to
oral posaconzale , which is often continued for several
months until attainment of both clinical and radiographic
resolution.
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Key Points
This case represents a rare and difficult diagnosis of
pulmonary mucormycosis in a patient with hematologic
malignancy. While a rapidly progressive disease with a
high mortality rate, the patient in this case experienced a
favorable outcome. Diagnosis was made only after invasive
testing and successful treatment was achieved with an
extended course of high dose intravenous ambisome.
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